Financial Ratios Fortis Healthcare Limited
Equities
FORTIS
INE061F01013
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 844.00 INR | +0.30% |
|
-5.85% | -4.52% |
| 22/01 | Fortis Healthcare says inquiry directed against third party officers for perjury | RE |
| 20/01 | Fortis Healthcare: in top shape |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 0.66 | 4.12 | 4.03 | 4.45 | 5.53 | |||||
Return on Total Capital | 0.87 | 5.76 | 5.67 | 6.11 | 6.99 | |||||
Return On Equity % | -0.81 | 11.51 | 8.38 | 7.75 | 9.13 | |||||
Return on Common Equity | -1.72 | 9.03 | 8.77 | 8.04 | 9.34 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 51.41 | 56.41 | 57.48 | 36.41 | 58.9 | |||||
SG&A Margin | 3.28 | 3.96 | 4.9 | 4.96 | 5.33 | |||||
EBITDA Margin % | 8.5 | 17.41 | 16.09 | 17.16 | 19.26 | |||||
EBITA Margin % | 2.96 | 13.54 | 12.53 | 13.75 | 15.73 | |||||
EBIT Margin % | 2.93 | 13.3 | 12.46 | 13.28 | 15.34 | |||||
Income From Continuing Operations Margin % | -1.39 | 13.82 | 10.05 | 9.36 | 10.4 | |||||
Net Income Margin % | -2.72 | 9.71 | 9.35 | 8.69 | 9.94 | |||||
Net Avail. For Common Margin % | -2.72 | 9.71 | 9.35 | 8.69 | 9.94 | |||||
Normalized Net Income Margin | -0.7 | 3.21 | 6.53 | 6.93 | 8.32 | |||||
Levered Free Cash Flow Margin | -28.24 | 9.29 | 2.93 | 27.26 | -19.35 | |||||
Unlevered Free Cash Flow Margin | -26.05 | 10.59 | 3.92 | 28.11 | -18.21 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.36 | 0.5 | 0.52 | 0.54 | 0.58 | |||||
Fixed Assets Turnover | 0.78 | 1.11 | 1.23 | 1.27 | 1.29 | |||||
Receivables Turnover (Average Receivables) | 8.42 | 11.79 | 11.52 | 11.4 | 11.02 | |||||
Inventory Turnover (Average Inventory) | 25.28 | 24.97 | 21.79 | 38.07 | 28.74 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 0.84 | 0.89 | 0.99 | 0.45 | 0.92 | |||||
Quick Ratio | 0.71 | 0.73 | 0.67 | 0.39 | 0.81 | |||||
Operating Cash Flow to Current Liabilities | 0.39 | 0.68 | 0.58 | 0.35 | 0.89 | |||||
Days Sales Outstanding (Average Receivables) | 43.33 | 30.96 | 31.7 | 32.11 | 33.12 | |||||
Days Outstanding Inventory (Average Inventory) | 14.44 | 14.62 | 16.75 | 9.61 | 12.7 | |||||
Average Days Payable Outstanding | 106.86 | 86.93 | 93.72 | 60.42 | 87.34 | |||||
Cash Conversion Cycle (Average Days) | -49.1 | -41.35 | -45.28 | -18.69 | -41.52 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 22.78 | 17.91 | 11.43 | 13.5 | 26.99 | |||||
Total Debt / Total Capital | 18.56 | 15.19 | 10.26 | 11.89 | 21.26 | |||||
LT Debt/Equity | 17.85 | 14.74 | 9.32 | 11.52 | 25.21 | |||||
Long-Term Debt / Total Capital | 14.54 | 12.5 | 8.36 | 10.15 | 19.85 | |||||
Total Liabilities / Total Assets | 39.78 | 41.03 | 34.85 | 35.61 | 33.03 | |||||
EBIT / Interest Expense | 0.84 | 6.37 | 7.8 | 9.78 | 8.41 | |||||
EBITDA / Interest Expense | 2.74 | 8.76 | 10.61 | 13.33 | 11.05 | |||||
(EBITDA - Capex) / Interest Expense | 1.19 | 6.95 | 6.16 | 3.26 | 5.08 | |||||
Total Debt / EBITDA | 3.97 | 1.2 | 0.87 | 0.93 | 1.58 | |||||
Net Debt / EBITDA | 2.89 | 0.81 | 0.52 | 0.44 | 1.26 | |||||
Total Debt / (EBITDA - Capex) | 9.14 | 1.51 | 1.5 | 3.79 | 3.43 | |||||
Net Debt / (EBITDA - Capex) | 6.65 | 1.01 | 0.9 | 1.82 | 2.73 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | -13 | 41.87 | 10.14 | 9.45 | 12.88 | |||||
Gross Profit, 1 Yr. Growth % | -20.76 | 55.67 | 12.23 | 8.72 | 15.41 | |||||
EBITDA, 1 Yr. Growth % | -35.67 | 186.89 | 1.78 | 14.08 | 26.34 | |||||
EBITA, 1 Yr. Growth % | -61.84 | 526.05 | 1.91 | 16.65 | 28.68 | |||||
EBIT, 1 Yr. Growth % | -61.97 | 542.84 | 3.17 | 16.69 | 29.93 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -161.39 | -1.51T | -19.87 | 1.93 | 25.44 | |||||
Net Income, 1 Yr. Growth % | -289.45 | -605.75 | 6.05 | 1.72 | 29.28 | |||||
Normalized Net Income, 1 Yr. Growth % | -136.47 | -746.93 | 124.24 | 16.08 | 35.64 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -289.45 | -605.54 | 6.1 | 1.69 | 29.32 | |||||
Accounts Receivable, 1 Yr. Growth % | -8.27 | 11.89 | 13.56 | 7.95 | 24.95 | |||||
Inventory, 1 Yr. Growth % | -1.81 | 60.1 | -0.05 | -12.56 | 7.33 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | -0.59 | -0.67 | -1.29 | 14.39 | 7.65 | |||||
Total Assets, 1 Yr. Growth % | -1.7 | 6.54 | 4.62 | 6.88 | 3.03 | |||||
Tangible Book Value, 1 Yr. Growth % | -18.5 | -26.63 | 55.62 | 14.63 | 41.99 | |||||
Common Equity, 1 Yr. Growth % | -8.13 | 0.95 | 17.22 | 5.81 | 16.36 | |||||
Cash From Operations, 1 Yr. Growth % | 183.01 | 78.25 | -4.99 | 33.79 | 29.44 | |||||
Capital Expenditures, 1 Yr. Growth % | 40.17 | -1.38 | 107.54 | 110.73 | -10.14 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -743.02 | -146.66 | -65.29 | 912.93 | -180.04 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -469.1 | -157.68 | -59.19 | 684.06 | -173.05 | |||||
Dividend Per Share, 1 Yr. Growth % | - | - | - | 0 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | -5.04 | 11.1 | 25.01 | 9.8 | 11.19 | |||||
Gross Profit, 2 Yr. CAGR % | -9.06 | 11.06 | 32.18 | -11.79 | 40.95 | |||||
EBITDA, 2 Yr. CAGR % | 22.11 | 36.73 | 70.88 | 9 | 20.26 | |||||
EBITA, 2 Yr. CAGR % | 83.66 | 57.41 | 152.59 | 10.65 | 22.78 | |||||
EBIT, 2 Yr. CAGR % | 88.42 | 56.36 | 157.53 | 9.72 | 23.41 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | -49.89 | 193.84 | 235.7 | -9.62 | 13.08 | |||||
Net Income, 2 Yr. CAGR % | -39.41 | 209.54 | 131.6 | 3.87 | 14.68 | |||||
Normalized Net Income, 2 Yr. CAGR % | 19.65 | 53.61 | 280.88 | 61.34 | 25.48 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -45.59 | 209.48 | 131.6 | 3.87 | 14.68 | |||||
Accounts Receivable, 2 Yr. CAGR % | -12.05 | 1.31 | 12.72 | 10.72 | 16.14 | |||||
Inventory, 2 Yr. CAGR % | 16.53 | 25.38 | 26.5 | -6.51 | -3.12 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 0.62 | -0.63 | -0.98 | 6.26 | 10.97 | |||||
Total Assets, 2 Yr. CAGR % | -3.39 | 2.34 | 5.58 | 5.74 | 4.94 | |||||
Tangible Book Value, 2 Yr. CAGR % | -8.52 | -22.67 | 6.86 | 33.56 | 27.58 | |||||
Common Equity, 2 Yr. CAGR % | -3.71 | -3.69 | 8.78 | 11.37 | 10.96 | |||||
Cash From Operations, 2 Yr. CAGR % | 64.91 | 124.6 | 30.14 | 12.75 | 31.6 | |||||
Capital Expenditures, 2 Yr. CAGR % | 62.14 | 17.57 | 43.07 | 109.13 | 37.61 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -2.66 | 73.22 | -59.75 | 88.13 | 184.93 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -12.65 | 45.91 | -51.48 | 78.88 | 139.49 | |||||
Dividend Per Share, 2 Yr. CAGR % | - | - | - | - | 0 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | -4.04 | 8.56 | 10.78 | 19.59 | 10.84 | |||||
Gross Profit, 3 Yr. CAGR % | -6.66 | 8.79 | 11.45 | 6.6 | 12.45 | |||||
EBITDA, 3 Yr. CAGR % | 2.09 | 63.03 | 23.92 | 50.49 | 14.63 | |||||
EBITA, 3 Yr. CAGR % | -1.53 | 179.79 | 36.17 | 97.16 | 16.53 | |||||
EBIT, 3 Yr. CAGR % | -1.17 | 183.65 | 36.13 | 97.8 | 16.26 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -60.83 | 52.28 | 90.55 | 125.63 | 0.81 | |||||
Net Income, 3 Yr. CAGR % | -52.27 | 22.91 | 116.6 | 76.05 | 11.73 | |||||
Normalized Net Income, 3 Yr. CAGR % | -20.67 | 110.01 | 74.25 | 156.31 | 52.27 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -57.88 | 14.39 | 116.6 | 76.03 | 11.74 | |||||
Accounts Receivable, 3 Yr. CAGR % | -4.5 | -4.7 | 5.24 | 11.11 | 15.27 | |||||
Inventory, 3 Yr. CAGR % | 4.83 | 29.54 | 16.26 | 11.85 | -2.11 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 19.39 | 0.19 | -0.85 | 3.9 | 6.72 | |||||
Total Assets, 3 Yr. CAGR % | 8.97 | -0.19 | 3.09 | 6.01 | 4.83 | |||||
Tangible Book Value, 3 Yr. CAGR % | 7.36 | -15 | -2.37 | 9.39 | 36.31 | |||||
Common Equity, 3 Yr. CAGR % | 14.64 | -2.18 | 2.83 | 7.78 | 13.01 | |||||
Cash From Operations, 3 Yr. CAGR % | -0.5 | 69.24 | 68.61 | 31.35 | 18.06 | |||||
Capital Expenditures, 3 Yr. CAGR % | 6.65 | 37.38 | 42.09 | 62.78 | 57.81 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 88.04 | -23.82 | 1.37 | 18.2 | 41.56 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 49.21 | -23.94 | -4.58 | 22.66 | 32.77 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | -0.82 | 4.57 | 6.67 | 9.05 | 10.94 | |||||
Gross Profit, 5 Yr. CAGR % | -3.21 | 3.88 | 7.28 | 0.03 | 11.89 | |||||
EBITDA, 5 Yr. CAGR % | 14.49 | 25.37 | 25.77 | 38.78 | 23.01 | |||||
EBITA, 5 Yr. CAGR % | 56.13 | 41.87 | 44.59 | 93.05 | 31.42 | |||||
EBIT, 5 Yr. CAGR % | 38.39 | 41.97 | 44.96 | 93.99 | 30.89 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 7.18 | 10.51 | -7.49 | 23.6 | 54.65 | |||||
Net Income, 5 Yr. CAGR % | 42.89 | 5.65 | -10.22 | 14.91 | 67.95 | |||||
Normalized Net Income, 5 Yr. CAGR % | 73.04 | -6.63 | 48.59 | 88.99 | 52.8 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 65.96 | -3.68 | -16.71 | 10.06 | 67.95 | |||||
Accounts Receivable, 5 Yr. CAGR % | 0.61 | 1.61 | 2.05 | 1.19 | 9.47 | |||||
Inventory, 5 Yr. CAGR % | 5.04 | 14.83 | 13.02 | 13.7 | 8.08 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 26.04 | 9.89 | 10.78 | 2.57 | 3.72 | |||||
Total Assets, 5 Yr. CAGR % | 9.05 | 4.11 | 7.6 | 2.14 | 3.83 | |||||
Tangible Book Value, 5 Yr. CAGR % | 3.96 | -8.47 | 7.16 | 1.84 | 8.66 | |||||
Common Equity, 5 Yr. CAGR % | 8.02 | 3.73 | 12.26 | 3.03 | 6.01 | |||||
Cash From Operations, 5 Yr. CAGR % | 20.05 | -2.18 | 10.78 | 43.86 | 52.69 | |||||
Capital Expenditures, 5 Yr. CAGR % | -1.02 | -4.94 | 19.95 | 62.52 | 40.28 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 83.31 | 50.51 | 1.49 | 9.37 | 53.46 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 52.14 | 57.41 | -4.8 | 7.08 | 37.88 |
- Stock Market
- Equities
- FORTIS Stock
- Financials Fortis Healthcare Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















